Literature DB >> 21482500

Bridging therapies and liver transplantation in acute liver failure, 10 years of MARS experience from Finland.

T Kantola1, M Ilmakunnas, A-M Koivusalo, H Isoniemi.   

Abstract

Acute liver failure is a life-threatening condition in the absence of liver transplantation option. The aetiology of liver failure is the most important factor determining the probability of native liver recovery and prognosis of the patient. Extracorporeal liver assist devices like MARS (Molecular Adsorbent Recirculating System) may buy time for native liver recovery or serve as bridging therapy to liver transplantation, with reduced risk of cerebral complications. MARS treatment may alleviate hepatic encephalopathy even in patients with a completely necrotic liver. Taking this into account, better prognostic markers than hepatic encephalopathy should be used to assess the need for liver transplantation in acute liver failure.

Entities:  

Mesh:

Year:  2011        PMID: 21482500     DOI: 10.1177/145749691110000103

Source DB:  PubMed          Journal:  Scand J Surg        ISSN: 1457-4969            Impact factor:   2.360


  6 in total

1.  Outcome of patients treated with molecular adsorbent recirculating system albumin dialysis: A national multicenter study.

Authors:  Christophe Camus; Clara Locher; Faouzi Saliba; Bernard Goubaux; Agnès Bonadona; Laurence Lavayssiere; Catherine Paugam; Alice Quinart; Olivier Barbot; Sébastien Dharancy; Bertrand Delafosse; Nicolas Pichon; Hélène Barraud; Arnaud Galbois; Benoit Veber; Sophie Cayot; Bruno Souche
Journal:  JGH Open       Date:  2020-05-17

2.  MARS therapy, the bridging to liver retransplantation - Three cases from the Hungarian liver transplant program.

Authors:  Balázs Pőcze; János Fazakas; Gergely Zádori; Dénes Görög; László Kóbori; Eszter Dabasi; Tamás Mándli; László Piros; Anikó Smudla; Tamás Szabó; Eva Toronyi; Szabolcs Tóth; Gellért Tőzsér; Gyula Végső; Attila Doros; Balázs Nemes
Journal:  Interv Med Appl Sci       Date:  2013-07-04

3.  Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center.

Authors:  Clément Monet; Audrey De Jong; Yassir Aarab; Lauranne Piron; Albert Prades; Julie Carr; Fouad Belafia; Gérald Chanques; Boris Guiu; Georges-Philippe Pageaux; Samir Jaber
Journal:  Crit Care       Date:  2022-09-19       Impact factor: 19.334

Review 4.  Role of liver support systems in the management of post hepatectomy liver failure: A systematic review of the literature.

Authors:  Kamil Pufal; Alexander Lawson; James Hodson; Mansoor Bangash; Jaimin Patel; Chris Weston; Thomas van Gulik; Bobby Vm Dasari
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-05-31

5.  Causes and outcomes of acute liver failure in China.

Authors:  Pan Zhao; Chunya Wang; Weiwei Liu; Gang Chen; Xinying Liu; Xi Wang; Bao Wang; Liming Yu; Yanrong Sun; Xiaoming Liang; Haozhen Yang; Fei Zhang
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

6.  Early predictors of acute hepatitis B progression to liver failure.

Authors:  Qing-Fang Xiong; Tian Xiong; Ping Huang; Yan-Dan Zhong; Hua-Li Wang; Yong-Feng Yang
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.